On June 17, 2021, Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), announced the pricing of its initial public offering of 7,000,000 American depositary shares (ADSs), each representing seven ordinary shares, at a public offering price of $18.00 per ADS. The total gross proceeds to Ambrx from the offering are expected to be $126.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini Goodrich & Rosati represented Ambrx on patent matters related to the IPO.

Ambrx has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 ADSs at the initial public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Ambrx. The shares began trading on the New York Stock Exchange on June 18, 2021, under the ticker symbol “AMAM.” The offering closed on June 22, 2021.

The Wilson Sonsini team that advised Ambrx on patent matters related to the transaction was led by Uale Taotafa and included Feng Tian and Mike Hostetler.

For more information, please see Ambrx’s press release.